Clinical Trial: Efficacy of Nivolumab in Treating Sepsis-Induced Immunosuppression in Chronically Critically Ill Patients: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial (China)

China, Oct. 29 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy of Nivolumab in Treating Sepsis-Induced Immunosuppression in Chronically Critically Ill Patients: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135383

Registration Time: 2026/10/29

Type: Interventional study

Primary Sponsor: Shenzhen People's Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=348435

Published by HT Digital Content Services with permission from Health Daily Digest....